Top Anti Cancer Imported Medicine Drugs in India - Pharama Five
Help Desk :+916374297988

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org

Best Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) Medicine in India

Buy Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) Medicine in India

Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab)

Medicine name : Enhertu

Generic name : Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab

Manufactured By : Daiichi Sankyo / AstraZeneca

Indications : 1st-line unresectable or metastatic HER2-positive breast cancer

Medicine Description : A targeted therapy for HER2-positive unresectable or metastatic breast cancer, Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) combines an antibody-drug conjugate with HER2-targeted therapy to block HER2 signaling and deliver anticancer treatment to HER2-expressing cancer cells. It is used as a first-line treatment for eligible patients with unresectable or metastatic HER2-positive breast cancer.

Product Introduction

Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) is a targeted anticancer treatment used to treat certain HER2-positive breast cancers and gastric cancers. It targets HER2 proteins found at high levels on certain cancer cells and helps deliver anticancer treatment directly to these cells, helping to destroy cancer cells while limiting exposure to healthy cells.

Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) is administered as an intravenous (IV) infusion by a doctor or qualified healthcare professional, according to the treatment schedule prescribed by your doctor. Treatment is generally given at regular intervals, and attending all scheduled appointments is important for maintaining effective treatment. Staying well hydrated, eating a balanced diet, and following your healthcare team's advice may help you manage treatment-related effects.

Common side effects of Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) may include nausea, fatigue, decreased appetite, vomiting, diarrhea, constipation, hair loss, and decreased blood cell counts, which may increase the risk of infections. Avoid alcohol unless your doctor advises otherwise, and inform your doctor if you have existing lung or heart problems. Enhertu may cause serious lung conditions such as interstitial lung disease (ILD) or pneumonitis, as well as other serious reactions. Pregnancy and breastfeeding should be avoided during treatment because it may harm an unborn baby or breastfed infant.

Uses Of Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab)

Treatment of HER2-Positive Stomach and Breast Cancer

Benefits Of Enhertu

Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) is used to treat certain HER2-positive stomach and metastatic breast cancers, particularly when the disease has spread or progressed after previous treatments. It targets HER2 proteins on cancer cells and delivers anticancer treatment directly to them, helping to inhibit cancer-cell growth and destroy tumor cells. This targeted approach can help slow disease progression, reduce tumor burden, improve disease control, and support a better quality of life in eligible patients.

Side Effects Of Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab)

Some side effects of Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) may improve as the body adjusts to the treatment. Consult your doctor if they persist, become severe, or cause concern.

Common Side Effects of Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab)

  • Nausea
  • Fatigue
  • Hair loss
  • Constipation
  • Abdominal pain
  • Decreased white blood cell count
  • Decreased hemoglobin
  • Decreased neutrophil count
  • Decreased lymphocyte count
  • Low blood platelet count
How To Use Enhertu

Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) is administered as an intravenous infusion by a qualified healthcare professional according to the treatment schedule prescribed by your doctor. Enhertu is generally given once every three weeks, and premedications may be given to help prevent nausea and vomiting. When used with pertuzumab for first-line HER2-positive metastatic breast cancer, pertuzumab is administered after Enhertu. Regular medical check-ups and laboratory tests are important to monitor treatment response and possible side effects.

How Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) Works

Enhertu contains a HER2-directed antibody-drug conjugate that binds to HER2 proteins on cancer cells and enters the cells. Inside the cancer cell, the drug releases its DXd component, a topoisomerase I inhibitor that damages DNA and causes cancer-cell death. Pertuzumab is a separate HER2-targeted antibody that blocks HER2 signaling, providing an additional mechanism for inhibiting the growth and survival of HER2-positive cancer cells.

Safety Advice

AlcoholCONSULT YOUR DOCTOR

It is not known whether alcohol is safe during treatment. Consult your doctor before consuming alcohol.

PregnancyCONSULT YOUR DOCTOR

Enhertu may cause fetal harm and is not recommended during pregnancy unless your doctor determines that the potential benefits outweigh the risks.

BreastfeedingCONSULT YOUR DOCTOR

Enhertu may be unsafe during breastfeeding and could potentially harm the baby. Consult your doctor before breastfeeding during treatment.

DrivingCONSULT YOUR DOCTOR

It is not known whether Enhertu affects the ability to drive. Avoid driving if you experience symptoms that affect concentration, alertness, or reaction time.

KidneyCAUTION

Limited information is available regarding the use of Enhertu in patients with kidney disease. Inform your doctor about any kidney problems before treatment.

LiverCAUTION

Enhertu may be used in patients with mild liver impairment as prescribed by a doctor. Your doctor may monitor liver function during treatment.

Quick Tips
  • Take Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) exactly as prescribed and attend all scheduled infusions without missing appointments.
  • Report any new or worsening side effects to your doctor promptly so they can be managed early.
  • Reduce your risk of infections by washing your hands regularly, avoiding contact with sick people when possible, and keeping cuts and wounds clean.
  • Manage fatigue by getting adequate rest and choosing gentle activities such as short walks or stretching when you feel able.
  • Stay hydrated, eat nutritious meals, and seek emotional support from family, friends, or support groups during treatment.
  • Read More About - Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) from Pharma Five.
Faq

General Question

Enhertu (Fam-trastuzumab deruxtecan [T-DXd] + Pertuzumab) is a targeted cancer treatment used as a first-line therapy for eligible adults with unresectable or metastatic HER2-positive breast cancer. It combines HER2-targeted medicines to help slow cancer growth and progression.

Enhertu works by targeting HER2 proteins found on the surface of cancer cells. Fam-trastuzumab deruxtecan binds to HER2 and delivers the chemotherapy component directly into cancer cells, while pertuzumab blocks HER2 signaling. Together, they help inhibit the growth and survival of HER2-positive cancer cells.

Enhertu is intended for adults with unresectable or metastatic HER2-positive breast cancer who are eligible for first-line treatment. It should be administered under the supervision of an experienced oncologist.

Enhertu is administered as an intravenous infusion by a healthcare professional. The dose and infusion schedule are determined by your oncologist based on your body weight, medical condition, treatment response, and the prescribed combination therapy. Do not attempt to administer this medicine yourself.

Common side effects of Enhertu may include nausea, fatigue, vomiting, decreased appetite, constipation, hair loss, low blood cell counts, and changes in liver function tests. Your healthcare team can recommend appropriate measures to manage these effects.

Enhertu can cause serious side effects, including interstitial lung disease or pneumonitis, which may cause cough, shortness of breath, or difficulty breathing. It may also cause heart problems, severe low blood cell counts, liver problems, and infusion-related reactions. Contact your healthcare provider immediately if you experience serious or worsening symptoms.

The duration of Enhertu treatment varies according to your response to therapy and overall health. Treatment is generally continued as directed by your oncologist until the disease progresses or side effects become unacceptable. Do not stop treatment without consulting your healthcare team.

It is advisable to avoid or limit alcohol while receiving Enhertu unless your doctor advises otherwise. Alcohol may worsen certain treatment-related effects such as fatigue, nausea, or dizziness. Discuss alcohol consumption with your healthcare provider.

Enhertu may cause harm to an unborn baby and should not generally be used during pregnancy unless specifically prescribed by a doctor. Women who can become pregnant should use effective contraception during treatment and follow their doctor's advice regarding contraception after treatment.

Enhertu may interact with other medicines and treatments. Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins, supplements, and herbal products you are taking. Your healthcare team will assess potential interactions before and during treatment.

If you miss a scheduled Enhertu infusion, contact your oncology team as soon as possible to arrange another appointment. Do not try to make up a missed treatment on your own. Your doctor will determine the appropriate timing for the next dose.

Enhertu is administered by intravenous infusion, so it is not taken with food in the same way as oral medicines. You may generally eat and drink normally unless your healthcare team provides specific instructions before or during the infusion.

Tell your doctor about any existing lung, heart, liver, or other medical conditions before starting Enhertu. Regular blood tests and other monitoring may be required during treatment. Report new or worsening cough, breathing difficulties, chest discomfort, fever, or other unusual symptoms promptly.

Enhertu should be stored and handled by the healthcare facility according to the manufacturer's storage and preparation requirements. Patients should not store or prepare Enhertu at home. Follow your healthcare provider's instructions regarding treatment and handling.

Enhertu should be administered only by qualified healthcare professionals at an appropriate medical facility. It is available through authorized hospitals, pharmacies, or medicine suppliers with a valid prescription. Pharma Five assists in its procurement.